Jade Biosciences, Inc. Operating Lease Cost
Jade Biosciences, Inc. (JBIO) reported Operating Lease Cost of $115.00 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-04-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-04-25
- Jade Biosciences, Inc. operating lease, cost for the quarter ending 2025-03-31 was $115.00K, a 1.77% increase year-over-year.
- Jade Biosciences, Inc. operating lease, cost for the quarter ending 2024-12-31 was $115.00K, a 12.88% decline year-over-year.
- Jade Biosciences, Inc. operating lease, cost for the quarter ending 2024-09-30 was $115.00K, a 3.60% increase year-over-year.
- Jade Biosciences, Inc. operating lease, cost for the quarter ending 2024-06-30 was $114.00K, a 2.70% increase year-over-year.
- Jade Biosciences, Inc. operating lease, cost for fiscal 2024 was $458.00K, a 1.29% decline from fiscal 2023.
- Jade Biosciences, Inc. operating lease, cost for fiscal 2023 was $464.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-03-31 | $115.00K 10-Q · filed 2025-04-25 | $230.00K derived: sum of 2 quarters · filed 2025-04-25 | $345.00K derived: sum of 3 quarters · filed 2025-04-25 | $459.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $230.00K derived: sum of 2 quarters · filed 2025-03-27 | $344.00K derived: sum of 3 quarters · filed 2025-03-27 | $458.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $115.00K 10-Q · filed 2024-11-12 | $229.00K derived: sum of 2 quarters · filed 2024-11-12 | $343.00K 10-Q · filed 2024-11-12 | $474.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-06-30 | $114.00K 10-Q · filed 2024-08-12 | $228.00K 10-Q · filed 2024-08-12 | $359.00K derived: sum of 3 quarters · filed 2025-04-25 | $470.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $113.00K 10-Q · filed 2025-04-25 | $245.00K derived: sum of 2 quarters · filed 2025-04-25 | $356.00K derived: sum of 3 quarters · filed 2025-04-25 | $467.00K derived: sum of 4 quarters · filed 2025-04-25 |
| 2023-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $243.00K derived: sum of 2 quarters · filed 2025-03-27 | $354.00K derived: sum of 3 quarters · filed 2025-03-27 | $464.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $111.00K 10-Q · filed 2024-11-12 | $222.00K derived: sum of 2 quarters · filed 2024-11-12 | $332.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $111.00K 10-Q · filed 2024-08-12 | $221.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $111.00K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $112.00K 10-Q · filed 2023-11-13 | $204.00K derived: sum of 2 quarters · filed 2023-11-13 | $254.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $92.00K 10-Q · filed 2023-08-14 | $142.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $51.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |